Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 1/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.44 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.44 |
| ▸ | FLT1 | P17948 | 1/20 | 0.44 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.41 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.40 |
| ▸ | TTR | P02766 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL505648 | 0.85 | ALDH1A1 (0.45) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL913705 | 0.84 | PDGFRB (0.46) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL31159174 | 0.84 | PDGFRB (0.49) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL2046728 | 0.84 | PDGFRB (0.49) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL4022732 | 0.84 | PDGFRB (0.46) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL21357291 | 0.84 | TTR (0.37) | VCAM1TTRMAPTKCNMA1 | |
| SCHEMBL21357288 | 0.84 | ALDH1A1 (0.50) | ALDH1A1KMT2AKDM4EMAPT | |
| SCHEMBL29858635 | 0.83 | TTR (0.50) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL205671 | 0.83 | TTR (0.50) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL13987139 | 0.83 | ALDH1A1 (0.50) | PDGFRBFGFR1PDGFRAFLT1FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731631-A1 | BENZAMIDAZOLE DIAZAPINONE PARP INHIBITORS AND METHODS OF USE | Valo Health, Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-4731630-A1 | HOMOPHTHALAZINONE INDOLE PARP INHIBITORS AND METHODS OF USE | Valo Health, Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| WO-2024261712-A1 | BENZAMIDAZOLE DIAZAPINONE PARP INHIBITORS AND METHODS OF USE | VALO HEALTH, INC. (US) | 2024-12-26 | — | — | WO | disclosed |
| WO-2024261711-A1 | HOMOPHTHALAZINONE INDOLE PARP INHIBITORS AND METHODS OF USE | VALO HEALTH, INC. (US) | 2024-12-26 | — | — | WO | disclosed |
| CN-111868060-B | Dihydropyridino phthalazinone derivatives, preparation method and application thereof | 上海艾力斯医药科技股份有限公司 | 2023-06-09 | — | — | CN | disclosed |
| EP-3341375-B1 | PROCESS FOR PREPARING PARP INHIBITOR, CRYSTALLINE FORMS, AND USES THEREOF | BEIGENE LTD (KY) | 2022-04-13 | — | — | EP | disclosed |
| CN-111868060-A | Dihydropyridophthalazinone derivative, preparation method and application thereof | 上海艾力斯医药科技股份有限公司 | 2020-10-30 | — | — | CN | disclosed |
| US-10457680-B2 | Process for preparing a PARP inhibitor, crystalline forms, and uses thereof | BEIGENE, LTD. (KY) | 2019-10-29 | — | — | US | disclosed |
| WO-2019174607-A1 | DIHYDROPYRIDOPHTHALAZINONE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 上海艾力斯医药科技有限公司 | 2019-09-19 | — | — | WO | disclosed |
| WO-2019174607-A1 | DIHYDROPYRIDOPHTHALAZINONE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 上海艾力斯医药科技有限公司 | 2019-09-19 | — | — | WO | disclosed |
| CN-101616892-A | The tricyclic compound that is used for the treatment of the iron imbalance | XENON PHARMACEUTICALS INC | 2009-12-30 | — | — | CN | disclosed |
| EP-2061755-A1 | TRICYCLIC COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2009-05-27 | — | — | EP | disclosed |
| US-20090069408-A1 | TRICYCLIC COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2009-03-12 | — | — | US | disclosed |
| US-20090069408-A1 | TRICYCLIC COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2009-03-12 | — | — | US | disclosed |
| WO-2008109840-A1 | TRICYCLIC COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2008-09-12 | — | — | WO | disclosed |
| WO-2008109840-A1 | TRICYCLIC COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2008-09-12 | — | — | WO | disclosed |
| EP-1208104-B1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASES | AGOURON PHARMA (US) | 2005-01-19 | — | — | EP | disclosed |
| US-6548494-B1 | 3,4-dihydro-2H-(1,4)diazepino(6,7,1-hi)indol-1-one or 1-thione derivatives where indole C3 could also be N; use treating cancers as well as stroke, head trauma, and neurodegenerative diseases | AGOURON PHARMACEUTICALS, INC. | 2003-04-15 | — | — | US | disclosed |
| EP-1208104-A2 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASES | AGOURON PHARMACEUTICALS, INC. (US) | 2002-05-29 | — | — | EP | disclosed |
| WO-2001016136-A2 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASES | AGOURON PHARMACEUTICALS, INC. (US) | 2001-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069408-A1 | TRICYCLIC COMPOUNDS USEFUL IN TREATING IRON DISORDERS | TFRC, SLC40A1, FECH | PDGFRB 4832/4885FGFR1 1834/4885PDGFRA 4753/4885 |
| US-10457680-B2 | Process for preparing a PARP inhibitor, crystalline forms, and uses thereof | PARP1, PARP2, PARP11 | PDGFRB 490/4885FGFR1 806/4885PDGFRA 272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.